- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
ARCHIVE Published on: 2021-09-20
Legal and Scientific Basis
There is no legal or scientific basis for denying organ transplants to legal medical cannabis patients.
This widespread policy is not based on any state or federal regulations. There is no statue or regulation that would prevent a legal medical cannabis patient from receiving an anatomical gift, and neither UNOS or the Organ Procurement and Transplantation Network (OPTN) have guidelines or policies to that effect. Medical cannabis patients are most commonly denied for testing positive for using a drug of abuse. That policy predates the emerging science about the medical use of cannabis and its legalization in thirty-four states and the District of Columbia.
The policy of denying anatomical gifts to legal medical cannabis patients is also not based on science. Clinical research shows that medical cannabis and compounds in medical cannabis have beneficial immune-suppressive and anti-inflammatory effects.[i] Compounds in medical cannabis may prolong graft survival in transplant patients,[ii] and there is no association between cannabis use and lower survival rates.[iii] Furthermore, hypothetical concerns about the harmful effects of contaminates can be easily addressed by an emerging industry aimed at testing commercially available medical cannabis for molds, mildew, pesticides, etc.
[i] Rom, S., & Persidsky, Y. (2013). Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation. Journal of Neuroimmune Pharmacology. doi:10.1007/s11481-013-9445-9
[ii] Robinson, R. H., Meissler, J. J., Breslow-Deckman, J. M., Gaughan, J., Adler, M. W., & Eisenstein, T. K. (2013). Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. Journal of Neuroimmune Pharmacology, 8(5), 1239–1250. doi:10.1007/s11481-013-9485-1
[iii] Ranney, D. N., Acker, W. B., Holou, Al, S. N., Ehrlichman, L., Lee, D. S., Lewin, S. A., et al. (2009). Marijuana Use in Potential Liver Transplant Candidates. American Journal of Transplantation, 9(2), 280–285. doi:10.1111/j.1600-6143.2008.02468.x